NEWS HIGHLIGHTSMedia Articles Related to Lucentis (Ranibizumab)
Cataract Surgery Doesn't Worsen Macular Degeneration: Study
Source: MedicineNet Eye Care Specialty [2009.11.10]
Title: Cataract Surgery Doesn't Worsen Macular Degeneration: Study
Category: Health News
Created: 11/9/2009 4:10:00 PM
Last Editorial Review: 11/10/2009
Cataract Surgery Doesn't Worsen Macular Degeneration: Study (HealthDay)
Source: Y! Health Eyes & Vision News [2009.11.09]
HealthDay - MONDAY, Nov. 9 (HealthDay News) -- Cataract surgery doesn't
appear to speed the progression of age-related macular degeneration (AMD),
according to a new study that challenges the belief that treating one
cause of vision loss worsens the other.
Nearly 18 Million Will Have Macular Degeneration by 2050
Source: MedicineNet Macular Degeneration (Age-Related Type) Specialty [2009.04.15]
Title: Nearly 18 Million Will Have Macular Degeneration by 2050
Category: Health News
Created: 4/15/2009 2:00:00 AM
Last Editorial Review: 4/15/2009
Macular Degeneration (Age-Related Type)
Source: MedicineNet Eyeglasses, Sunglasses, and Magnifiers Specialty [2007.12.27]
Title: Macular Degeneration (Age-Related Type)
Category: Diseases and Conditions
Created: 7/23/1999 6:05:00 PM
Last Editorial Review: 12/27/2007
Patients Win With Immediate Avastin Payment Reversal
Source: Eye Health / Blindness News From Medical News Today [2009.11.20]
Following efforts by the American Academy of Ophthalmology with the help of the American Society of Retina Specialists, the Macula Society, the Retina Society and Congressional allies, the Center for Medicare and Medicaid Services (CMS) said that it will retract an Oct. 1 payment policy for small doses of Avastin. Avastin, a cancer drug, is used in smaller doses to treat eye diseases such as age-related macular degeneration (AMD).
Published Studies Related to Lucentis (Ranibizumab)
Bevacizumab vs Ranibizumab for Age-related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial. [2009.10.02]
PURPOSE: To report early outcomes of a prospective, double-masked, controlled trial comparing bevacizumab (Avastin; Genentech Inc, South San Francisco, California, USA) to ranibizumab (Lucentis; Genentech Inc) for the treatment of age-related macular degeneration. DESIGN: Prospective, double-masked, randomized clinical trial... CONCLUSION: Early results of a head-to-head, randomized, double-masked, prospective, single-center controlled trial between bevacizumab and ranibizumab show no difference in efficacy between the two treatments for choroidal neovascularizaton in the treatment of age-related macular degeneration. As this study conveys results of a small number of patients, further studies with larger sample sizes are needed in order to establish statistical significance.
A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. [2009.09]
OBJECTIVE: To evaluate the safety and efficacy of intravitreal ranibizumab in a large population of subjects with neovascular age-related macular degeneration (AMD). DESIGN: Twelve-month randomized (cohort 1) or open-label (cohort 2) multicenter clinical trial. PARTICIPANTS: A total of 4300 subjects with angiographically determined subfoveal choroidal neovascularization (CNV) secondary to AMD... CONCLUSIONS: Intravitreal ranibizumab was safe and well tolerated in a large population of subjects with neovascular AMD. Ranibizumab had a beneficial effect on VA. Future investigations will seek to establish optimal dosing regimens for persons with neovascular AMD. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: a prospective study. [2009.04]
PURPOSE: To compare 1) intravitreal ranibizumab, 2) intravitreal ranibizumab plus photodynamic therapy (PDT), and 3) intravitreal triamcinolone plus PDT in retinal angiomatous proliferation... CONCLUSION: All groups resulted in stabilization of the disease, while a significant trend towards better visual acuity and anatomic restoration of the affected area was observed in the intravitreal triamcinolone & PDT group.
Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. [2009.01]
OBJECTIVE: To compare patient-reported visual function in those with neovascular age-related macular degeneration treated with ranibizumab or verteporfin photodynamic therapy (PDT)... CONCLUSIONS: Patients treated with ranibizumab were more likely to report clinically meaningful improvements in visual function through 24 months compared with those treated with verteporfin PDT. Application to Clinical Practice Ranibizumab treatment in neovascular age-related macular degeneration can improve patient-reported visual function. Trial Registration clinicaltrials.gov Identifier: NCT00061594.
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. [2009.01]
OBJECTIVE: The 2-year, phase III trial designated Anti-vascular endothelial growth factor (VEGF) Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization (CNV) in Age-related Macular Degeneration (ANCHOR) compared ranibizumab with verteporfin photodynamic therapy (PDT) in treating predominantly classic CNV... CONCLUSIONS: In this 2-year study, ranibizumab provided greater clinical benefit than verteporfin PDT in patients with age-related macular degeneration with new-onset, predominantly classic CNV. Rates of serious adverse events were low. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
Clinical Trials Related to Lucentis (Ranibizumab)
Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema [Recruiting]
This study will evaluate the clinical efficacy of intra-vitreal injections of Ranibizumab
(Lucentis) in the treatment of Diabetic Macular Edema as compared to grid/focal laser.
Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-Related Macular Degeneration (AMD) [Recruiting]
The purposes of this study is to determine if combination reduced fluence photodynamic
therapy and Ranibizumab has:
Similar efficacy to Ranibizumab (Lucentis) alone. The ability to reduce the number of
intravitreal injection of Ranibizumab or a 13 month period The ability to reduce the number
of PDT treatments. The study will also collect information on the safety of combination
therapy and single therapy.
Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization [Recruiting]
This study will evaluate the effect of combination therapy with verteporfin photodynamic
therapy and ranibizumab on visual acuity and anatomic outcomes compared to ranibizumab
monotherapy and the durability of response observed in patients with choroidal
neovascularization secondary to age-related macular degeneration.
Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration [Recruiting]
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus
(rapamycin) formulation in combination with Lucentis in patients with sub-foveal choroidal
neovascularization secondary to age-related macular degeneration.
Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema [Recruiting]
This study is designed to confirm the efficacy and safety of ranibizumab (0. 5 mg) as
adjunctive therapy when added to laser photocoagulation and/or mono-therapy in patients with
visual impairment due to diabetic macular edema.
|
